Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Hervouet 2005 Carcinogenesis"

From Bioblast
Line 1: Line 1:
{{Publication
{{Publication
|title=Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, Godinot C (2005) A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26: 531-539.
|title=Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, Godinot C (2005) A new role for the von Hippel-Lindau tumor suppressor protein: Stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26: 531-539.
|info=[http://www.ncbi.nlm.nih.gov/pubmed/15604095 PMID: 15604095]
|info=[http://www.ncbi.nlm.nih.gov/pubmed/15604095 PMID: 15604095]
|authors=Hervouet E, Demont J, Pecina P, Vojtiskova A, Houstek J, Simonnet H, Godinot C
|authors=Hervouet E, Demont J, Pecina P, Vojtiskova A, Houstek J, Simonnet H, Godinot C
Line 10: Line 10:
}}
}}
{{Labeling
{{Labeling
|area=Respiration, nDNA;cell genetics, mt-Medicine
|diseases=Cancer
|couplingstates=OXPHOS
|instruments=Oxygraph-2k
|instruments=Oxygraph-2k
|injuries=Cancer; Apoptosis; Cytochrome c, Genetic Defect; Knockdown; Overexpression
|couplingstates=OXPHOS
}}
}}

Revision as of 00:07, 12 August 2013

Publications in the MiPMap
Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, Godinot C (2005) A new role for the von Hippel-Lindau tumor suppressor protein: Stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26: 531-539.

» PMID: 15604095

Hervouet E, Demont J, Pecina P, Vojtiskova A, Houstek J, Simonnet H, Godinot C (2005) Carcinogenesis

Abstract: Although mitochondrial deficiency in cancer has been described by Warburg, many years ago, the mechanisms underlying this impairment remain essentially unknown. Many types of cancer cells are concerned and, in particular, clear cell renal carcinoma (CCRC). In this cancer, the tumor suppressor gene, VHL (von Hippel-Lindau factor) is invalidated. Previous studies have shown that the transfection of the VHL gene in VHL-deficient cells originating from CCRCs could suppress their ability to form tumors when they were injected into nude mice. However, various additional genetic alterations are observed in such cancer cells. In order to investigate whether VHL invalidation was related to the mitochondrial impairment, we have studied the effects of wild-type VHL transfection into VHL-deficient 786-0 or RCC10 cells on their oxidative phosphorylation (OXPHOS) subunit contents and functions. We show that the presence of wild-type VHL protein (pVHL) increased mitochondrial DNA and respiratory chain protein contents and permitted the cells to rely on their mitochondrial ATP production to grow in the absence of glucose. In parallel to mtDNA increase, the presence of pVHL up regulated the mitochondrial transcription factor A, as shown by western blot analysis. In conclusion, in CCRCs, pVHL deficiency is one of the factors responsible for down-regulation of the biogenesis of OXPHOS complexes. Keywords: CCRC, clear cell renal carcinoma, COX, cytochrome c oxidase, FCCP, Carbonyl cyanide 4-trifluoromethoxyphenylhydrazone, HIF, Hypoxia inducible factor, mtDNA, Mitochondrial DNA, NRF1 and NRF2, nuclear respiratory factor 1 and 2, OXPHOS, Oxidative phosphorylation, PGC1, Peroxisome proliferator-activated receptor γ (PPAR-γ) coactivator 1, PRC, PGC1 regulated co-activator 1, pVHL, von Hippel-Lindau protein, TFAM, mitochondrial transcription factor A, TMRM, tetramethylrhodamine methyl ester, VHL, von Hippel-Lindau gene

O2k-Network Lab: CZ_Prague_Houstek J, CZ Prague Bioenergetics


Labels: MiParea: Respiration, nDNA;cell genetics, mt-Medicine  Pathology: Cancer 




Coupling state: OXPHOS 

HRR: Oxygraph-2k